The identification and characterization of tumor-associated antigens (TAAs) and their use in
antigen mini-arrays for cancer immunodiagnosis has been of interest recently as an …

The discovery of tumor-associated antigens (TAA) in certain human malignancies has
prompted renewed efforts to develop antigen-specific immunotherapy of cancer. However …

Abstract Purpose: Immunostimulatory monoclonal antibodies (ISmAb) that unleash antitumor
immune responses are showing efficacy in cancer clinical trials. Anti-B7-H1 (PD-L1) …

Unlike traditional cancer therapies, cancer vaccines (CVs) harness a high specificity of the
host's immunity to kill tumor cells. CVs can train and bolster the patient's immune system to …

Purpose: Hepatocellular carcinoma (HCC) can express various cancer-testis antigens
including NY-ESO-1, members of the SSX family, members of the MAGE family, SCP-1, and …

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with a
poor prognosis and limited therapeutic options. Alpha-fetoprotein (AFP), an established …

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and is often
diagnosed at an advanced stage. We have investigated α-fetoprotein (AFP) as a tumor …

Patients with hepatocellular carcinoma (HCC) have a poor prognosis and limited therapeutic
options. Alpha‐fetoprotein (AFP) is often expressed at high levels in HCC and is an …

It is accepted that both helper and CTLs play a critical role in immune antitumor responses.
Thus, the design of effective immune-based therapies for cancer relies in the identification of …

Tumor T cell antigens are both diagnostically and therapeutically valuable molecules. A
large number of new peptides are examined as potential tumor epitopes each year, yet there …